Calling all Investors
Our first product to serve these markets is the Aurora Tissue Imaging system. We estimate annual the addressable US/European market for Aurora is approximately $1B for the urological indications of bladder and prostate.
The company is currently in the clinic training the AI-Algorithm for use in TURBT, funded in part by a NIH/NCI grant. The company plans for FDA approval of Aurora and first sales in bladder by the end of 2024. We are also beginning algorithm training in prostate with Dr. Vipul Patel, a world- renowned robotic prostate cancer surgeon at Advent Health Orlando, Florida.
DR. VIPUL PATEL Collaborator
CytoVeris has entered a collaborative clinical development agreement with the world-renowned surgeon Dr. Vipul Patel to bring AI-enabled surgical visualization to Robotic prostate cancer surgery.
DR. VIPUL PATEL
Director of the Global Robotics Institute
Bringing A.I. enabled surgical margin visualization to RARP to enhance patient outcomes.
“A new robot doesn’t make me a better surgeon… I need enhanced visualization to better understand anatomy, including tumors and critical structures”
Dr. Patel is one fo the most experienced roboitc surgeons in the world and has personall perfomed over 16,000 roboti prostatectomies
Dr. Patel also will serve as a consultant to CytoVeris and his vision will guide the product development for ex-vivi & in-vivo prostrate merging visualization.
Customer Value Proposition
- Intraoperative visualization of target tissue enables more precise excisional surgery
- No dyes or imaging agents
- Reduction in repeat procedures, related cost,s and post-op complications.
- Favorable economics in a value-based care paradigm
- Fits into the established surgical workflow.
- It does not replace or threaten pathology as the “gold standard.”
- Establishes the surgeon and the institution as a “Center of Excellence” for treatment of urological cancers
Advanced Imaging Strategically Vital in Robotics
The robotic market expanding rapidly CAGR ~ 10%
Robotic surgery platform providers are all looking for new tools or “apps” for the devices – these are their keys to competitive advantage and adoption.
“There are massive opportunities combining new sensing modalities with machine vision to identify tissue types and disease boundaries … … This is what LIDAR is to autonomous vehicles.”
– Gary Guthart, CEO of Intuitive Surgical
Key development milestones for CytoVeris in 2023 will be the development and demonstration of an in-vivo probe-based implementation of the CytoVeris platform
Technology Platform is Scalable for Expanding into Strategically-Relevant Markets
Learn More of investing in the future.
The company is currently in the clinic training the AI-Algorithm for use in TURBT, funded in part by an NIH/NCI grant. The company plans for FDA approval of Aurora and the first sales in bladder by the end of 2024. We are also beginning algorithm training in prostate with Dr. Vipul Patel, a world- renowned robotic prostate cancer surgeon at Advent Health Orlando, Florida.
The product development roadmap also takes CytoVeris into additional anatomical areas and to the development of a robotic probe for in vivo tissue visualization and identification which will further expand the market and have value to strategic partner/acquirers.
Clinical Activities: Urology